EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inactivation of TRPM7 Kinase Targets AKT Signaling and Cyclooxygenase-2 Expression in Human CML Cells

Birgit Hoeger iD, Wiebke Nadolni, Sarah Hampe, Kilian Hoelting, Marco Fraticelli, Nadja Zaborsky, Anna Madlmayr, Viktoria Sperrer, Laura Fraticelli, Lynda Addington, Dirk Steinritz, Vladimir Chubanov und 6 weitere

Function · 25.09.2023 · 4 (6)

DOI: 10.1093/function/zqad053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Function, online erschienen am 15.09.2023. Verfasst von Birgit Hoeger und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Johannes Kepler University Linz, Altenbergerstr. 69, 4040 Linz and Krankenhausstr. 5, 4020 Linz, Austria. Hauptthemen laut MEDLINE: TRPM Cation Channels, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclooxygenase-2 (COX-2) is a key regulator of inflammation. High constitutive COX-2 expression enhances survival and proliferation of cancer cells, and adversely impacts antitumor immunity. The expression of COX-2 is modulated by various signaling pathways. Recently, we identified the melastatin-like transient-receptor-potential-7 (TRPM7) channel-kinase as modulator of immune homeostasis. TRPM7 protein is essential for leukocyte proliferation and differentiation, and upregulated in several cancers. It comprises of a cation channel and an atypical α-kinase, linked to inflammatory cell signals and associated with hallmarks of tumor progression. A role in leukemia has not been established, and signaling pathways are yet to be deciphered. We show that inhibiting TRPM7 channel-kinase in chronic myeloid leukemia (CML) cells results in reduced constitutive COX-2 expression. By utilizing a CML-derived cell line, HAP1, harboring CRISPR/Cas9-mediated TRPM7 knockout, or a point mutation inactivating TRPM7 kinase, we could link this to reduced activation of AKT serine/threonine kinase and mothers against decapentaplegic homolog 2 (SMAD2). We identified AKT as a direct in vitro substrate of TRPM7 kinase. Pharmacologic blockade of TRPM7 in wildtype HAP1 cells confirmed the effect on COX-2 via altered AKT signaling. Addition of an AKT activator on TRPM7 kinase-dead cells reconstituted the wildtype phenotype. Inhibition of TRPM7 resulted in reduced phosphorylation of AKT and diminished COX-2 expression in peripheral blood mononuclear cells derived from CML patients, and reduced proliferation in patient-derived CD34+ cells. These results highlight a role of TRPM7 kinase in AKT-driven COX-2 expression and suggest a beneficial potential of TRPM7 blockade in COX-2-related inflammation and malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TRPM Cation ChannelsLeukemia, MyeloidLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansProto-Oncogene Proteins c-aktCyclooxygenase 2Leukocytes, MononuclearInflammationProtein Serine-Threonine Kinases

Stichwörter der Autor:innen

AKT signalingCMLCOX-2TRPM7channel-kinase

Substanzen

Proto-Oncogene Proteins c-aktCyclooxygenase 2TRPM Cation ChannelsTRPM7 protein, humanProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Institute of Pharmacology, Johannes Kepler University Linz, Altenbergerstr. 69, 4040 Linz and Krankenhausstr. 5, 4020 Linz, Austria.
  • Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-Universität München, Goethestr. 33, 80336 Munich, Germany.
  • Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, Austria.
  • Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Müllner Hauptstr. 48, 5020 Salzburg, Austria.
  • Cancer Cluster Salzburg, 5020 Salzburg, Austria.

ORCID-Profile: Birgit Hoeger, Roland Geisberger, Susanna Zierler

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Hoeger, B., Nadolni, W., Hampe, S., Hoelting, K., Fraticelli, M., Zaborsky, N., Madlmayr, A., Sperrer, V., Fraticelli, L., Addington, L., Steinritz, D., Chubanov, V., Geisberger, R., Greil, R., Breit, A., Boekhoff, I., Gudermann, T., & Zierler, S. (2023). Inactivation of TRPM7 Kinase Targets AKT Signaling and Cyclooxygenase-2 Expression in Human CML Cells. Function, 4(6). https://doi.org/10.1093/function/zqad053

Vancouver

Hoeger B, Nadolni W, Hampe S, Hoelting K, Fraticelli M, Zaborsky N, et al. Inactivation of TRPM7 Kinase Targets AKT Signaling and Cyclooxygenase-2 Expression in Human CML Cells. Function. 2023;4(6). doi:10.1093/function/zqad053

BibTeX
@article{Hoeger2023,
  author = {Hoeger, Birgit and Nadolni, Wiebke and Hampe, Sarah and Hoelting, Kilian and Fraticelli, Marco and Zaborsky, Nadja and Madlmayr, Anna and Sperrer, Viktoria and Fraticelli, Laura and Addington, Lynda and Steinritz, Dirk and Chubanov, Vladimir and Geisberger, Roland and Greil, Richard and Breit, Andreas and Boekhoff, Ingrid and Gudermann, Thomas and Zierler, Susanna},
  title = {Inactivation of TRPM7 Kinase Targets AKT Signaling and Cyclooxygenase-2 Expression in Human CML Cells},
  journal = {Function},
  year = {2023},
  volume = {4},
  number = {6},
  doi = {10.1093/function/zqad053}
}
Kostenlos starten →